<DOC>
	<DOCNO>NCT02901925</DOCNO>
	<brief_summary>The primary study objective determine microdoses ABY-029 lead detectable signal sample tissue EGFR pathology score ≥ 1 base histological staining . The secondary study objective ass diagnostic accuracy ABY-029 detection iFI intraoperative probe relative histopathology diagnosis , indicator ( e.g . proliferation , infiltration , etc . ) gold standard , measure molecular uptake concentration ABY-029 resect specimen .</brief_summary>
	<brief_title>A Microdose Evaluation Study ABY-029 Recurrent Glioma</brief_title>
	<detailed_description>The investigator plan sample size 6-12 patient open label , single center , clinical trial ABY-029 . Administration occur single intravenous injection subject recurrent glioma , approximately 1-3 hour prior surgery . The protocol safety study since physiological effect expect microdose level ABY-029 . Rather , dose select determine fluorescence signal detect wide-field image technology signal-to-noise ratio 10 , consider necessary subsequent assessment diagnostic performance ABY-029 tumor biomarker sufficient guide surgical resection future . No diagnostic therapeutic intent propose , administration study drug intend alter extent plan brain tumor resection surgical procedure .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Preoperative diagnosis recurrent highgrade glioma EGFR positive tissue prior surgery . 2 . Tumor judge suitable open cranial resection base preoperative imaging study . 3 . Valid inform consent subject . 4 . Age ≥ 18 year old . 1 . Pregnant woman woman breast feeding . 2 . Patients experimental antiEGFR targeted therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ABY-029</keyword>
	<keyword>Affibody</keyword>
	<keyword>Molecular Fluorescence-Guided Surgery</keyword>
	<keyword>Epidermal Growth Factor Receptor ( EGFR )</keyword>
</DOC>